Blood Screening Market Size, Share & Trends Analysis Report By Product (Reagent, Instrument), By Technology (NAT, ELISA, CLIA & EIA, NGS, Western Blotting), By Region, And Segment Forecasts, 2018 - 2024

Industry Insights

The global blood screening market size was valued at USD 1.6 billion in 2015 and is projected to grow at a CAGR of 10.2% over the forecast period. Blood screening is a process in which donated blood is screened for various infectious diseases such as HBV, HCV, HIV1, and HIV2. High growth of this market is attributed to rising blood donations, increase in the incidence of infectious diseases, and government initiatives. 

Initiatives by the various organizations and governments increase awareness about donation and screening before transfusion. According to the WHO, approximately 108 million blood donations are collected every year across the globe. About 50% of these blood donations collected from high-income countries which is home to less than 20% of the total population. Hence, rising awareness coupled with the high demand for safe blood create opportunities in emerging countries.

Furthermore, in 2010, the rate of screening for hepatitis B, hepatitis C, and HIV viruses increased as compared to previous years with almost 100% in most of the countries. To motivate volunteers, the WHO established a goal to provide safe blood access to the entire world by 2020. Such initiatives increase voluntary donations and are likely to propel the market during the forecast period.

Australia Red Cross launched two new initiatives to enhance voluntary donation on 14^th June 2016, which is a world blood donor day. The first initiative is an SMS alert and second is a toolkit that reduces the anxiety of the first-time donor and, thereby, increases voluntary donation in the country.

Product Insights

Reagent dominated in 2015 and is expected to maintain its dominance over the forecast period. Higher accuracy and specificity in detecting presence and type of various elements in a small sample would drive the market.

In addition, reagents are cost-effective for customers and give a high return on investment to the vendors. High cost and reusable nature of instruments restraint the growth of instrument segment in the blood screening market during the forecast period 2016 - 2024.

Instrument accounted for a significant share in the market due to introduction of devices in the market after their marketing approval. For instance, in October 2017, the FDA approved Roche’s Cobas Zika donor screening test for Zika virus. This will prevent the spread of Zika virus in the U.S. through blood donations.

Technology Insights

Nucleic acid amplification test (NAT) is expected to grow at the fastest rate owing to its high sensitivity and specificity for viral nucleic acid. The test detects nucleic acid earlier than other screening methods and, thus, narrows the window period of HBV, HCV, and HIV infections.

NAT was introduced in developed countries initially in the 1990s and early 2000. About 33 countries in the world implemented NAT for HIV and around 27 countries for hepatitis B virus till 2014. The methods that fall under this segment are polymerase chain reaction, ligase chain reaction, and transcription-mediated amplification.

In October 2016, Roche received the U.S.FDA approval for their next generation cobas MPX donor screening test to prevent the spread of viruses through blood transfusion. Cobas MPX assay is a NAT for the detection of five viruses HIV-1 Group O, HIV-1 Group M, HIV-2, HBV, and HCV, from a single sample.

ELISA accounted the second largest share of the market. The growth of this technology is attributed to continuous development to increase its specificity, low cost as compared to NAT, and increasing prevalence of infectious diseases in the Asia Pacific region. There are various ELISA generations available in the market.

Regional Insights

In 2015, North America accounted for the largest revenue share. The presence of key industry players, increased adoption of blood screening process, stringent FDA regulations for transfusion, and greater patient affordability are responsible for maintaining its position during the forecast period.

Vela Diagnostics received CE mark for its real-time PC- based Sentosa SA ZIKV PCR Test. The blood screening test for Zikacan identifies Zika virus infection in a donor. Furthermore, Roche launched next-generation viral load assay in March 2015 for HBV in Europe. It is a COBAS HBV quantitative nucleic acid test for COBAS 6800/8800 Systems. Hence, launch and adoption of such new technologies in the region are likely to further boost the industry in Europe.

Asia Pacific is the fastest growing region due to increasing awareness among people about blood donation, rising patient affordability, and growing focus of key industry players on emerging countries in the region. China, Japan, India, Singapore, and Australia are major contributing countries in the Asia Pacific region.

Blood Screening Market Share Insights

Some of the key players in the industry include Becton Dickinson and Company, Thermo Fisher Scientific., Ortho-Clinical Diagnostics, Inc., Grifols, Danaher Corporation (Beckman Coulter), Abbott Laboratories; Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd.; and Siemens AG

Development of new products and partnership or collaborations for the development and commercialization of products are the key strategies adopted by the companies to capture the market. For instance, Grifols received CE mark for the Procleix HEV assay, which uses NAT to detect hepatitis E virus. The test was developed in partnership with Hologic, Inc. Hence, collaboration for commercialization and development is likely to propel the industry during the forecast period.

Report Scope

Segments covered in the report

This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the global blood screening market report based on technology, product, and region:

• Blood Screening Technology Outlook (Revenue, USD Million; 2013 - 2024)

  • Nucleic Acid Amplification Test (NAT)

  • ELISA

  • Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

  • Next-Generation Sequencing (NGS)

  • Western Blotting

• Blood Screening Product Outlook (Revenue, USD Million; 2013 - 2024)

  • Reagent

  • Instrument

• Blood Screening Regional Outlook (Revenue, USD Million; 2013 - 2024)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

  • Asia Pacific

    • Japan

    • China

    • India

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa